Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge

Thomas Geisbert, Michael Bailey, Lisa Hensley, Clement Asiedu, Joan Geisbert, Daphne Stanley, Anna Honko, Joshua Johnson, Sabue Mulangu, Maria Grazia Pau, Jerome Custers, Jort Vellinga, Jenny Hendriks, Peter Jahrling, Mario Roederer, Jaap Goudsmit, Richard Koup, Nancy J. Sullivan

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

The use of adenoviruses (Ad) as vaccine vectors against a variety of pathogens has demonstrated their capacity to elicit strong antibody and cell-mediated immune responses. Adenovirus serotype C vectors, such as Ad serotype 5 (Ad5), expressing Ebolavirus (EBOV) glycoprotein (GP), protect completely after a single inoculation at a dose of 1010 viral particles. However, the clinical application of a vaccine based on Ad5 vectors may be hampered, since impairment of Ad5 vaccine efficacy has been demonstrated for humans and nonhuman primates with high levels of preexisting immunity to the vector. Ad26 and Ad35 segregate genetically from Ad5 and exhibit lower seroprevalence in humans, making them attractive vaccine vector alternatives. In the series of studies presented, we show that Ad26 and Ad35 vectors generate robust antigen-specific cell-mediated and humoral immune responses against EBOV GP and that Ad5 immune status does not affect the generation of GP-specific immune responses by these vaccines. We demonstrate partial protection against EBOV by a single-shot Ad26 vaccine and complete protection when this vaccine is boosted by Ad35 1 month later. Increases in efficacy are paralleled by substantial increases in T- and B-cell responses to EBOV GP. These results suggest that Ad26 and Ad35 vectors warrant further development as candidate vaccines for EBOV.

Original languageEnglish (US)
Pages (from-to)4222-4233
Number of pages12
JournalJournal of Virology
Volume85
Issue number9
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Ebolavirus
vector vaccines
Adenoviridae
Primates
Immunity
serotypes
Vaccines
immunity
vaccines
glycoproteins
Glycoproteins
cell-mediated immunity
Adenovirus Vaccines
Serogroup
Seroepidemiologic Studies
Humoral Immunity
virion
humoral immunity
Virion
seroprevalence

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge. / Geisbert, Thomas; Bailey, Michael; Hensley, Lisa; Asiedu, Clement; Geisbert, Joan; Stanley, Daphne; Honko, Anna; Johnson, Joshua; Mulangu, Sabue; Pau, Maria Grazia; Custers, Jerome; Vellinga, Jort; Hendriks, Jenny; Jahrling, Peter; Roederer, Mario; Goudsmit, Jaap; Koup, Richard; Sullivan, Nancy J.

In: Journal of Virology, Vol. 85, No. 9, 05.2011, p. 4222-4233.

Research output: Contribution to journalArticle

Geisbert, T, Bailey, M, Hensley, L, Asiedu, C, Geisbert, J, Stanley, D, Honko, A, Johnson, J, Mulangu, S, Pau, MG, Custers, J, Vellinga, J, Hendriks, J, Jahrling, P, Roederer, M, Goudsmit, J, Koup, R & Sullivan, NJ 2011, 'Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge', Journal of Virology, vol. 85, no. 9, pp. 4222-4233. https://doi.org/10.1128/JVI.02407-10
Geisbert, Thomas ; Bailey, Michael ; Hensley, Lisa ; Asiedu, Clement ; Geisbert, Joan ; Stanley, Daphne ; Honko, Anna ; Johnson, Joshua ; Mulangu, Sabue ; Pau, Maria Grazia ; Custers, Jerome ; Vellinga, Jort ; Hendriks, Jenny ; Jahrling, Peter ; Roederer, Mario ; Goudsmit, Jaap ; Koup, Richard ; Sullivan, Nancy J. / Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge. In: Journal of Virology. 2011 ; Vol. 85, No. 9. pp. 4222-4233.
@article{06e937efde8c4bd59693b91540e96826,
title = "Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge",
abstract = "The use of adenoviruses (Ad) as vaccine vectors against a variety of pathogens has demonstrated their capacity to elicit strong antibody and cell-mediated immune responses. Adenovirus serotype C vectors, such as Ad serotype 5 (Ad5), expressing Ebolavirus (EBOV) glycoprotein (GP), protect completely after a single inoculation at a dose of 1010 viral particles. However, the clinical application of a vaccine based on Ad5 vectors may be hampered, since impairment of Ad5 vaccine efficacy has been demonstrated for humans and nonhuman primates with high levels of preexisting immunity to the vector. Ad26 and Ad35 segregate genetically from Ad5 and exhibit lower seroprevalence in humans, making them attractive vaccine vector alternatives. In the series of studies presented, we show that Ad26 and Ad35 vectors generate robust antigen-specific cell-mediated and humoral immune responses against EBOV GP and that Ad5 immune status does not affect the generation of GP-specific immune responses by these vaccines. We demonstrate partial protection against EBOV by a single-shot Ad26 vaccine and complete protection when this vaccine is boosted by Ad35 1 month later. Increases in efficacy are paralleled by substantial increases in T- and B-cell responses to EBOV GP. These results suggest that Ad26 and Ad35 vectors warrant further development as candidate vaccines for EBOV.",
author = "Thomas Geisbert and Michael Bailey and Lisa Hensley and Clement Asiedu and Joan Geisbert and Daphne Stanley and Anna Honko and Joshua Johnson and Sabue Mulangu and Pau, {Maria Grazia} and Jerome Custers and Jort Vellinga and Jenny Hendriks and Peter Jahrling and Mario Roederer and Jaap Goudsmit and Richard Koup and Sullivan, {Nancy J.}",
year = "2011",
month = "5",
doi = "10.1128/JVI.02407-10",
language = "English (US)",
volume = "85",
pages = "4222--4233",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge

AU - Geisbert, Thomas

AU - Bailey, Michael

AU - Hensley, Lisa

AU - Asiedu, Clement

AU - Geisbert, Joan

AU - Stanley, Daphne

AU - Honko, Anna

AU - Johnson, Joshua

AU - Mulangu, Sabue

AU - Pau, Maria Grazia

AU - Custers, Jerome

AU - Vellinga, Jort

AU - Hendriks, Jenny

AU - Jahrling, Peter

AU - Roederer, Mario

AU - Goudsmit, Jaap

AU - Koup, Richard

AU - Sullivan, Nancy J.

PY - 2011/5

Y1 - 2011/5

N2 - The use of adenoviruses (Ad) as vaccine vectors against a variety of pathogens has demonstrated their capacity to elicit strong antibody and cell-mediated immune responses. Adenovirus serotype C vectors, such as Ad serotype 5 (Ad5), expressing Ebolavirus (EBOV) glycoprotein (GP), protect completely after a single inoculation at a dose of 1010 viral particles. However, the clinical application of a vaccine based on Ad5 vectors may be hampered, since impairment of Ad5 vaccine efficacy has been demonstrated for humans and nonhuman primates with high levels of preexisting immunity to the vector. Ad26 and Ad35 segregate genetically from Ad5 and exhibit lower seroprevalence in humans, making them attractive vaccine vector alternatives. In the series of studies presented, we show that Ad26 and Ad35 vectors generate robust antigen-specific cell-mediated and humoral immune responses against EBOV GP and that Ad5 immune status does not affect the generation of GP-specific immune responses by these vaccines. We demonstrate partial protection against EBOV by a single-shot Ad26 vaccine and complete protection when this vaccine is boosted by Ad35 1 month later. Increases in efficacy are paralleled by substantial increases in T- and B-cell responses to EBOV GP. These results suggest that Ad26 and Ad35 vectors warrant further development as candidate vaccines for EBOV.

AB - The use of adenoviruses (Ad) as vaccine vectors against a variety of pathogens has demonstrated their capacity to elicit strong antibody and cell-mediated immune responses. Adenovirus serotype C vectors, such as Ad serotype 5 (Ad5), expressing Ebolavirus (EBOV) glycoprotein (GP), protect completely after a single inoculation at a dose of 1010 viral particles. However, the clinical application of a vaccine based on Ad5 vectors may be hampered, since impairment of Ad5 vaccine efficacy has been demonstrated for humans and nonhuman primates with high levels of preexisting immunity to the vector. Ad26 and Ad35 segregate genetically from Ad5 and exhibit lower seroprevalence in humans, making them attractive vaccine vector alternatives. In the series of studies presented, we show that Ad26 and Ad35 vectors generate robust antigen-specific cell-mediated and humoral immune responses against EBOV GP and that Ad5 immune status does not affect the generation of GP-specific immune responses by these vaccines. We demonstrate partial protection against EBOV by a single-shot Ad26 vaccine and complete protection when this vaccine is boosted by Ad35 1 month later. Increases in efficacy are paralleled by substantial increases in T- and B-cell responses to EBOV GP. These results suggest that Ad26 and Ad35 vectors warrant further development as candidate vaccines for EBOV.

UR - http://www.scopus.com/inward/record.url?scp=79955387781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955387781&partnerID=8YFLogxK

U2 - 10.1128/JVI.02407-10

DO - 10.1128/JVI.02407-10

M3 - Article

VL - 85

SP - 4222

EP - 4233

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 9

ER -